The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

MD Anderson Cancer Center received more than $29 million from the Cancer Prevention and Research Institute of Texas to support prevention programs, research efforts, and faculty recruitment.

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium on October 24.

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.

Sevabertinib monotherapy led to robust and durable responses in first-line and pretreated patients with HER2-mutant advanced non–small cell lung cancer.

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.

Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the management of immune-related adverse effects in advanced NSCLC.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.

Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss treatment and sequencing considerations in advanced non–small cell lung cancer.

The global cross-licensing agreement will facilitate work aimed at enhancing the development of inducible switch technologies for cell and gene therapies.

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

Jason Aboudi Mouabbi, MD, discusses neoadjuvant multi-agent chemotherapy in HER2+ breast cancer.

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.